Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
Dianthus Therapeutics' DNTH103, a selective C1s inhibitor, is in phase 2 trials for gMG, CIDP, and MMN, offering a differentiated, convenient dosing profile. DNTH103's selective targeting minimizes ...
11don MSN
The (metabolic) cost of life
There are “costs of life” that mechanical physics cannot calculate. A clear example is the energy required to keep specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback